Request Demo
Boehringer signs $1.3B deal with RNA biotech Ochre Bio to team up against MASH
22 Apr 2024
Phase 2
Boehringer Ingelheim has notched some success in the metabolic-associated steatohepatitis space so far this year.
Boehringer Ingelheim is making yet another bet that Rmetabolic-associated steatohepatitisg metabolic-associated steatohepatitis (MASH).
Boehringer Ingelheim is paying British biotech Ochre Bio $35 million in upfront and near-temetabolic-associated steatohepatitis (MASH)estigate “multiple targets” for chronic liver disease. Top of the list of indications will be MASH, previously known as nonalcoholic steatohepatitis (NASH).
Should any of the targets in the “multi-year” cOchre Bioion prove fruitful, Ochre is also in line for various clinical, regulatory and commercial milestones as well achronic liver diseasehich add up to a deal value north of $1 bMASHon.nonalcoholic steatohepatitis (NASH)
Ochre’s remit is developing RNA therapies that enhance the liver’s regenerative capabilities in order to halt or reverse chronic liver diseases. It’s far from the first time Boehringer has played in this space—the pharma kicked off the year signing a $2 billion biobucks deal with Suzhou Ribo Life Science and Ribocure Pharmaceuticals to see whether their RNAi drug platform that targets disease-causing genes specifically in liver cells could complement Boehringer’s own MASH expertise.
Six years earlier, Boehringer penned back-to-back partnerships with Dicerna Pharmaceuticals and MiNA Therapeutics coverinchronic liver diseases small activating RNA to treat BoehringerSuzhou Ribo Life ScienceRibocure PharmaceuticalsBoehringer
Boehringer put this morning’s deal with Oxford, U.K.-based Ochre in Dicerna PharmaceuticalsmitmeMiNA Therapeuticshe lives of people living with interconnected cardiovascular,MASHal and metabolic diseases, including MASH cirrhosis.”
“Our partnership with Ochre Bio is driven by a shared goal Ochrecelerate the development of new treatments for chronic liver diseases including MASH cirrhosis,cardiovascular, renal and metabolic diseasesmetabolic diMASH cirrhosish at Boehringer, said in the release.
“Ochre Bio brings to tOchre Biounique and exciting capabilities in liver disease research,” Tullin added. “We bchronic liver diseaseson of advanMASH cirrhosisnd machine learning coupled with human-cardiometabolic diseasesdels holds thBoehringerl to uncover novel regenerative pathways that will make a meaningful difference in the lives of those affected by chronic liver disease.”
BOchre Bio has already notched some success in the MASH space so faliver diseasewith the company’s Zealand Pharma-partnered glucagon/GLP-1 agonist survodutide demonstrating improvements in disease activity and liver scarring in a phase 2 trial in February.chronic liver disease
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.